Detailed Abstract
[BP Poster Presentation 3 - Biliary & Pancreas (Biliary Disease/Surgery)]
[BP PP 3-5] Significance Of Adjuvant Therapy For Distal Bile Duct Cancer
Yasuhiro YABUSHITA1 , Ryusei MATSUYAMA1 , Kizuki YUZA1 , Tomoaki TAKAHASHI1 , Kentaro MIYAKE1 , Yu SAWADA1 , Yuki HOMMA1 , Takafumi KUMAMOTO1 , Kzuhisa TAKEDA1 , Itaru ENDO*1
1 Department Of Gastroenterological Surgery, Yokohama City University School Of Medicine, JAPAN
Background : In our department, patients with invade other organs or have lymph node metastasis are considered high-risk factors and indicated for adjuvant therapy. In this study, we retrospectively evaluated the efficacy of adjuvant treatment for distal bile duct cancer with high-risk factors
Methods : Of the 160 cases of resected distal bile duct cancer between 2003 and 2021, 116 patients with high-risk factors were included in this study. Patients were divided into two groups: those who received adjuvant therapy (Adj(+)) and those who did not (Adj(-)).
Results : There were 69 cases in Adj(+) group and 47 cases in Adj(-) group. In Adj(+) group, 63% of patients received gemcitabine and 33% received S-1 as adjuvant therapy. Patients in Adj(+) group were significantly younger than those in Adj(-) group (69 vs 73 years old, p=0.003). Postoperative complications tended to be more frequent in patients in Adj(-) group (40.6% vs 57.4%, p=0.074). The median recurrence-free time was 29.1 months in Adj(+) group and 12.5 months in Adj(-) group (p=0.078). The median survival time was 44.2 months in Adj(+) group and 30.1 months in Adj(-) group (p=0.008).
Conclusions : Adjuvant therapy can prevent recurrence and prolong survival in the patients of distal bile duct cancer with high-risk patients. Old age and postoperative complications may be factors in failure to introduce adjuvant therapy.
Methods : Of the 160 cases of resected distal bile duct cancer between 2003 and 2021, 116 patients with high-risk factors were included in this study. Patients were divided into two groups: those who received adjuvant therapy (Adj(+)) and those who did not (Adj(-)).
Results : There were 69 cases in Adj(+) group and 47 cases in Adj(-) group. In Adj(+) group, 63% of patients received gemcitabine and 33% received S-1 as adjuvant therapy. Patients in Adj(+) group were significantly younger than those in Adj(-) group (69 vs 73 years old, p=0.003). Postoperative complications tended to be more frequent in patients in Adj(-) group (40.6% vs 57.4%, p=0.074). The median recurrence-free time was 29.1 months in Adj(+) group and 12.5 months in Adj(-) group (p=0.078). The median survival time was 44.2 months in Adj(+) group and 30.1 months in Adj(-) group (p=0.008).
Conclusions : Adjuvant therapy can prevent recurrence and prolong survival in the patients of distal bile duct cancer with high-risk patients. Old age and postoperative complications may be factors in failure to introduce adjuvant therapy.
SESSION
BP Poster Presentation 3
Poster Presentation 3/24/2023 2:50 PM - 3:50 PM